149 related articles for article (PubMed ID: 35665359)
1. Case Report: Rare Systemic and Aggressive ALK-Positive Histiocytosis With Recurrent Pancreatitis Treating by
Li Y; Shi C; Wu Y; He M; Xia X; Liu J; Jiang Y
Front Med (Lausanne); 2022; 9():840407. PubMed ID: 35665359
[TBL] [Abstract][Full Text] [Related]
2. ALK-positive histiocytosis with disseminated disease responded to alectinib: a case report.
Tian Y; Li J; Liu B; Xie H; Zheng M; Yao W
Ann Palliat Med; 2021 Sep; 10(9):10095-10101. PubMed ID: 34628929
[TBL] [Abstract][Full Text] [Related]
3. ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion.
Chang KTE; Tay AZE; Kuick CH; Chen H; Algar E; Taubenheim N; Campbell J; Mechinaud F; Campbell M; Super L; Chantranuwat C; Yuen ST; Chan JKC; Chow CW
Mod Pathol; 2019 May; 32(5):598-608. PubMed ID: 30573850
[TBL] [Abstract][Full Text] [Related]
4. Localized ALK-positive histiocytosis in a Chinese woman: report of a case in the lung with a novel EML4-ALK rearrangement.
Bai Y; Sun W; Niu D; Yang X; Diao X; Yu Y; Lin D
Virchows Arch; 2021 Dec; 479(6):1079-1083. PubMed ID: 33825946
[TBL] [Abstract][Full Text] [Related]
5. ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy.
Chan JK; Lamant L; Algar E; Delsol G; Tsang WY; Lee KC; Tiedemann K; Chow CW
Blood; 2008 Oct; 112(7):2965-8. PubMed ID: 18660380
[TBL] [Abstract][Full Text] [Related]
6. Case report: Systemic presentation of ALK-positive Histiocytosis.
Wei Y; Zhang R; Lin D; Chen X; Li L; Huang H
Front Oncol; 2024; 14():1366766. PubMed ID: 38706599
[TBL] [Abstract][Full Text] [Related]
7. Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib.
Zhou Y; Hurtado-Castillo M; Pandey O
Front Med (Lausanne); 2023; 10():1288849. PubMed ID: 38093982
[TBL] [Abstract][Full Text] [Related]
8. Multisystem ALK-positive histiocytosis: a multi-case study and literature review.
Liu W; Liu HJ; Wang WY; Tang Y; Zhao S; Zhang WY; Yan JQ; Liu WP
Orphanet J Rare Dis; 2023 Mar; 18(1):53. PubMed ID: 36915094
[TBL] [Abstract][Full Text] [Related]
9. ALK-Positive Histiocytosis: A Case Report and Literature Review.
Jaber OI; Jarrah DA; Hiasat M; Hussaini MA
Turk Patoloji Derg; 2021; 37(2):172-177. PubMed ID: 33973641
[TBL] [Abstract][Full Text] [Related]
10. Expanding the Phenotype of ALK-positive Histiocytosis: A Report of 2 Cases.
Huang H; Gheorghe G; North PE; Suchi M
Pediatr Dev Pathol; 2018; 21(5):449-455. PubMed ID: 29224419
[TBL] [Abstract][Full Text] [Related]
11. ALK-rearranged histiocytosis: Report of two cases with involvement of the central nervous system.
Rossi S; Gessi M; Barresi S; Tamburrini G; Giovannoni I; Ruggiero A; Colafati GS; Frassanito P; Carboni A; Alexandre A; Cacchione A; Trombatore P; Diomedi-Camassei F; Gaspari S; Gianno F; Marras CE; Cecinati V; Carai A; Mastronuzzi A; Alaggio R
Neuropathol Appl Neurobiol; 2021 Oct; 47(6):878-881. PubMed ID: 34048085
[TBL] [Abstract][Full Text] [Related]
12. ALK-positive Histiocytosis of the Breast: A Clinicopathologic Study Highlighting Spindle Cell Histology.
Kashima J; Yoshida M; Jimbo K; Izutsu K; Ushiku T; Yonemori K; Yoshida A
Am J Surg Pathol; 2021 Mar; 45(3):347-355. PubMed ID: 32826530
[TBL] [Abstract][Full Text] [Related]
13. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
[TBL] [Abstract][Full Text] [Related]
14. Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report.
Gu X; Wang W; Wu W; Zhang Y; Shao L; Santarpia M; Christopoulos P; Myall NJ; Shi Z; Lou G
Transl Lung Cancer Res; 2022 May; 11(5):902-909. PubMed ID: 35693284
[TBL] [Abstract][Full Text] [Related]
15.
Sun N; Zhuang Y; Zhang J; Chen S; Dai Y; Guo R
Onco Targets Ther; 2021; 14():5161-5166. PubMed ID: 34729013
[TBL] [Abstract][Full Text] [Related]
16. Local ALK-Positive Histiocytosis With Unusual Morphology and Novel
Tran TAN; Chang KTE; Kuick CH; Goh JY; Chang CC
Int J Surg Pathol; 2021 Aug; 29(5):543-549. PubMed ID: 33243034
[TBL] [Abstract][Full Text] [Related]
17. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
[TBL] [Abstract][Full Text] [Related]
18. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
Front Oncol; 2022; 12():761558. PubMed ID: 35237506
[TBL] [Abstract][Full Text] [Related]
19. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
20. Central nervous system relapse in a pediatric anaplastic large cell lymphoma patient with CLTC/ALK translocation treated with alectinib: A case report.
Yang J; Li J; Gu WY; Jin L; Duan YL; Huang S; Zhang M; Wang XS; Liu Y; Zhou CJ; Gao C; Zheng HY; Zhang YH
World J Clin Cases; 2020 May; 8(9):1685-1692. PubMed ID: 32420302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
